CoreLab Partners Launches Imaging Application
CoreLab Partners, Inc has launched a new advanced imaging application named ImagEngine.®
The ImagEngine® system is a software program which will be utilized exclusively by CoreLab Partners’ board-certified Radiologists to calibrate, read, annotate, and review digitized medical images. This advancement is an integral component of a technological suite of solutions to enhance productivity, improve quality, and accelerate timelines.
Various elements of the staged roll-outs will include:
The ability to load and display DICOM images, associated measurement and calibration objects
- Segmentation tools
- Registration tools to support multi-modality fusion with synchronized scrolling and lesion propagation
- Registration of multi-modality voxel volumes
- Calculates geometric and intensity based statistics
- Object tagging with meta-data such as user ID, anatomical site code and label
- Full integration with CoreLab Partners’ information flow, repository and Oracle Clinical database
- Support for centralized storage and retrieval of application configuration information based on project protocol.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
